Nanopublication

ID

http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g
Formats

Content

@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g> .
@prefix sub: <http://purl.org/np/RAymPzHleRaxxoSGl85qjP2e8Xbx6kETXMYV-2rrvg59g#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: a np:Nanopublication;
    np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_437> biolink:category biolink:Disease .
  
  sub:association a rdf:Statement;
    rdf:object <http://purl.obolibrary.org/obo/DOID_437>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00468>;
    rdfs:label "\"Quinine sulfate is contraindicated in patients with the following:    Prolongation of QT interval ( 4 Glucose-6-phosphate dehydrogenase (G6PD) deficiency ( 4 Myasthenia gravis ( 4 Known hypersensitivity to quinine, mefloquine, or quinidine ( 4 Optic neuritis ( 4 Quinine sulfate is contraindicated in patients with the following:  * Prolonged QT interval. One case of a fatal ventricular arrhythmia was reported in an elderly patient with a prolonged QT interval at baseline, who received quinine sulfate intravenously for  P. falciparum  [see WARNINGS AND PRECAUTIONS ( 5.3  * Glucose-6-phosphate dehydrogenase (G6PD) deficiency.  * Hemolysis can occur in patients with G6PD deficiency receiving quinine.  * Known hypersensitivity reactions to quinine.  * These include, but are not limited to, the following  [see WARNINGS AND PRECAUTIONS ( 5.6  * Thrombocytopenia  * Idiopathic thrombocytopenia purpura (ITP) and Thrombotic thrombocytopenic purpura (TTP)  * Hemolytic uremic syndrome (HUS)  * Blackwater fever (acute intravascular hemolysis, hemoglobinuria, and hemoglobinemia)  * Known hypersensitivity to mefloquine or quinidine: cross-sensitivity to quinine has been documented  [see WARNINGS AND PRECAUTIONS ( 5.6  * Myasthenia gravis. Quinine has neuromuscular blocking activity, and may exacerbate muscle weakness.  * Optic neuritis. Quinine may exacerbate active optic neuritis  [see ADVERSE REACTIONS ( 6\"";
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00468> biolink:category biolink:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "T3N3TGK5kHu+neLOtZXrtOnpSw3grcBqr1rVJrHngOeardHubJl2iz+jiYJ8cgDP9/IiglORHW1fpPFWcjjz+QIwrLDtmxl9ORr30gi+JcjE+QHuVh/QNeZCFlfK/GrE32Gig9oSpEvtA1qVESS+9oyxeuts3EJg0u9U+qdz2KY=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T18:44:18.224+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}